XML 51 R42.htm IDEA: XBRL DOCUMENT v3.22.2.2
Stockholders’ Equity (Details) - USD ($)
 1 Months Ended 6 Months Ended 12 Months Ended
Apr. 14, 2021
Feb. 09, 2021
Aug. 03, 2020
Aug. 03, 2020
Apr. 18, 2020
Apr. 15, 2020
Mar. 31, 2022
Jan. 31, 2022
Dec. 29, 2021
Jan. 18, 2021
Apr. 28, 2020
Apr. 17, 2020
Apr. 15, 2020
Jun. 30, 2022
Jun. 30, 2021
Dec. 31, 2021
Dec. 31, 2020
Mar. 10, 2021
Jul. 06, 2020
Nov. 30, 2019
Apr. 30, 2013
Stockholders’ Equity (Details) [Line Items]                                          
Preferred stock, shares authorized                           5,000,000   5,000,000 5,000,000        
Preferred stock, par value (in Dollars per share)                           $ 0.0001   $ 0.0001 $ 0.0001        
Converted preferred stock 4,049   4,000 4,000                                  
Convertible common stock 269,900   40,000 40,000                                  
Redemption value (in Dollars)       $ 400,000                                  
Exchange agreements, description                         On April 15, 2020, the Company entered into Exchange Agreements with the holders of its Series B Preferred Stock, which shares of Series B Preferred Stock were originally issued in November 2019. Pursuant to the Exchange Agreements, the holders agreed to exchange their 115 shares of Series B Preferred Stock with a stated value of $115,000 and 11,500 warrants issued in connection with the Series B Preferred Stock for an aggregate of 28,750 shares of the Company’s common stock at a price of $4.00 per share. After the exchanges, there are no shares of the Company’s Series B Preferred Stock outstanding. The Company issued 28,750 shares of common stock which was more than the shares that would have been issued at the original conversion price of $10.00 per share or 11,500 shares of common stock, an excess of 17,250 shares of common stock. The excess shares were valued at a price of $4.00 per share. Consequently, in connection with this share exchange, the Company recorded a deemed dividend on this extinguishment of $69,000 during the year ended December 31, 2020. Accordingly, there are no shares of Series B Preferred Stock issued and outstanding as of December 31, 2021 and 2020.                
Preferred stock conversion, description                           The Series C Convertible preferred stock and the February Warrants each contain a beneficial ownership limitation that restricts each of the investor’s ability to exercise the February Warrants and convert the Series C Convertible preferred stock such that the number of shares of the Company common stock held by each of them and their affiliates after such conversion or exercise does not exceed 4.99% (or, at the election of the Investor, 9.99%) of the Company’s then issued and outstanding shares of common stock.    The Series C Convertible Preferred Stock and the February Warrants each contain a beneficial ownership limitation that restricts each of the investor’s ability to exercise the February Warrants and convert the Series C Convertible Preferred Stock such that the number of shares of the Company common stock held by each of them and their affiliates after such conversion or exercise does not exceed 4.99% (or, at the election of the Investor, 9.99%) of the Company’s then issued and outstanding shares of common stock.           
Warrants term                           5 years   5 years          
Exercise price (in Dollars per share)                           $ 15   $ 15          
Subsequent financing, percentage                               50.00%          
Obligation percentage                               1.00%          
Placement agent warrants, description                           In addition, pursuant to the terms of the offering, the Company issued Bradley Woods & Co, Ltd. and Katalyst Securities LLC warrants (the “Placement Agent Warrants”) to purchase up to an aggregate of 57,013 shares of common stock, or 10% of the shares of common stock issuable upon conversion of the Series C Preferred Stock and February Warrant Shares sold in the offering. The Placement Agent Warrants are exercisable for a period of five years from the closing date of the offering at an exercise price of $17.50 per share, subject to adjustment.   In addition, pursuant to the terms of the offering, the Company issued Bradley Woods & Co, Ltd. and Katalyst Securities LLC warrants (the “Placement Agent Warrants”) to purchase up to an aggregate of 57,013 shares of common stock, or 10% of the shares of common stock issuable upon conversion of the Series C Preferred Stock and February Warrant Shares sold in the offering. The Placement Agent Warrants are exercisable for a period of five years from the closing date of the offering at an exercise price of $17.50 per share, subject to adjustment.          
Risk free interest rate                               0.50%          
Expected dividend yield                               0.00%          
Expected term                               5 years          
Expected volatility                               169.00%          
Aggregate grant date fair value of placement agent warrants (in Dollars)                               $ 1,106,000          
Shares of common stock                   170,000           12          
Proceeds from issuance of common stock (in Dollars)                               $ 2,115,733        
Subscription receivable (in Dollars)                                     $ 2,000    
Total subscription receivable (in Dollars)         $ 77,644                                
Common stock, par value (in Dollars per share)           $ 4             $ 4 $ 0.0001   $ 0.0001 $ 0.0001        
Investor invested amount (in Dollars)                               $ 100,000          
Liquidity damage, description                           If the Company fails to file the Registration Statement or have it declared effective by the dates set forth above, amongst other things, the Company will be obligated to pay the investors damages in the amount of 1% of their subscription amount, per month, until such events are satisfied.   If the Company fails to file the registration statement or have it declared effective by the dates set forth above, amongst other things, the Company is obligated to pay the investors liquidated damages in the amount of 1% of their subscription amount, per month, until such events are satisfied, subject to a cap of 6%.          
Recognized stock-based consulting fees (in Dollars)                           $ 107,970 $ 107,970 $ 578,924        
Prepaid expenses and other current assets (in Dollars)                               0 107,970        
Redemption value (in Dollars)                                    
Deemed dividend (in Dollars)                                 69,000        
Loss on debt extinguishment (in Dollars)                               $ (197,682)        
Convertible promissory notes (in Dollars)           $ 330,000                              
Warrants issued           33,000                              
Aggregate number of common stock           82,500                              
Stock-based compensation (in Dollars)                               $ 83,728          
Purchase agreement, description   On February 9, 2021, the Company entered into pursuant to securities purchase agreements with certain investors pursuant to which it sold warrants to purchase up to 285,066 shares of the Company’s common stock and 4,276 shares of the Company’s Series C Convertible preferred stock. The February Warrants are exercisable for a period of five years from the date of issuance at an exercise price of $15.00 per share, subject to adjustment. If, after a period of 180 days after the date of issuance of the February Warrants, a registration statement covering the resale of the February Warrant Shares is not effective, the holders may exercise the February Warrants by means of a cashless exercise. In addition, pursuant to the terms of the offering, the Company issued the Placement Agent Warrants to purchase up to an aggregate of 57,013 shares of common stock to its placement agents, or 10% of the shares of common stock issuable upon conversion of the Series C preferred stock and February Warrant Shares sold in the offering. The Placement Agent Warrants are exercisable for a period of five years from the closing date of the offering at an exercise price of $17.50 per share, subject to adjustment (see Series C Convertible Preferred Stock Financing above). Such warrants issued to various investors and to the placement agents were recorded as additional paid in capital with an offsetting debit applied against additional paid in capital, thus these warrants have no further accounting effect within the equity section.                                       
Shares authorized                           505,000,000              
Common stock, shares authorized                           500,000,000   500,000,000 500,000,000        
Gross proceeds (in Dollars)                               $ 7,020,526          
Subsequent financing, percentage                           50.00%              
Expired term                 Dec. 26, 2026                        
Employment agreement, description               Kou, exercisable at $10.00 per share and expires on January 31, 2032. The stock options vest as follows: (i) 6,000 stock options upon issuance; (ii) 5,000 vests on October 31, 2022 and; (iii) 5,000 vests on October 31, 2023.                          
Deferred compensation balance (in Dollars)                           $ 35,782              
Warrant [Member]                                          
Stockholders’ Equity (Details) [Line Items]                                          
Warrants term                   5 years                      
Exercise price (in Dollars per share)                   $ 10                      
Risk free interest rate                   0.46%                      
Expected term                   5 years                      
Expected volatility                   169.00%                      
Common stock, description           The Company issued 82,500 shares of common stock which was more than the shares that would have been issued at the original conversion price of $4.00 per share or 33,000 shares of common stock, an excess of 49,500 shares of common stock. The excess shares were valued at a price of $4.00 per share.                              
Loss on debt extinguishment (in Dollars)                                 $ 198,000        
Granted warrants to purchase shares                   5,000                      
Warrant, description                               The warrants were valued on the grant date at approximately $16.50 per warrant for a total of $83,728 using a Black-Scholes option pricing model with the following assumptions: stock price of $17.50 per share (based on the quoted trading price on the date of grant), volatility of 169%, expected term of five year, and a risk-free interest rate of 0.46%.          
Stock-based Compensation (in Dollars)                               $ 83,728          
Grant date price per warrant (in Dollars per share)                   $ 16.5                      
Warrant value (in Dollars)                   $ 83,728                      
Stock price (in Dollars per share)                   $ 17.5                      
Placement Agent Warrants [Member]                                          
Stockholders’ Equity (Details) [Line Items]                                          
Risk free interest rate                           0.50%              
Expected dividend yield                           0.00%              
Expected term                           5 years              
Expected volatility                           169.00%              
Aggregate grant date fair value of placement agent warrants (in Dollars)                           $ 1,106,000              
Minimum [Member]                                          
Stockholders’ Equity (Details) [Line Items]                                          
Authorized number of shares                                   100,000,000      
Maximum [Member]                                          
Stockholders’ Equity (Details) [Line Items]                                          
Authorized number of shares                                   500,000,000      
Subscription Agreements [Member]                                          
Stockholders’ Equity (Details) [Line Items]                                          
Conversion price per share (in Dollars per share)         $ 0.5                                
Shares of common stock         155,287                                
Proceeds from issuance of common stock (in Dollars)         $ 75,644                                
Subscription receivable (in Dollars)         $ 2,000                                
Securities Purchase Agreements [Member]                                          
Stockholders’ Equity (Details) [Line Items]                                          
Shares of common stock                     599,875                    
Proceeds from issuance of common stock (in Dollars)                     $ 2,399,500                    
Common stock, par value (in Dollars per share)                     $ 4                    
Placement agent fees (in Dollars)                     $ 242,950                    
Other offering expenses (in Dollars)                     118,460                    
Total net proceeds (in Dollars)                     $ 2,038,090                    
Advisory Agreements [Member]                                          
Stockholders’ Equity (Details) [Line Items]                                          
Shares of common stock                       102,347                  
Proceeds from issuance of common stock (in Dollars)                       $ 409,387                  
Common stock, par value (in Dollars per share)                       $ 4                  
Consulting Agreement [Member]                                          
Stockholders’ Equity (Details) [Line Items]                                          
Shares of common stock                       69,377                  
Proceeds from issuance of common stock (in Dollars)                       $ 277,508                  
Common stock, par value (in Dollars per share)                       $ 4                  
Employment Agreement [Member]                                          
Stockholders’ Equity (Details) [Line Items]                                          
Shares of common stock                       152,619                  
Proceeds from issuance of common stock (in Dollars)                       $ 610,476                  
Common stock, par value (in Dollars per share)                       $ 4                  
Recognized stock-based consulting fees (in Dollars)                                 610,476        
Exchange Agreements [Member]                                          
Stockholders’ Equity (Details) [Line Items]                                          
Common stock, description           On April 15, 2020, the Company entered into Exchange Agreements with the holders of certain convertible promissory notes. Pursuant to these Exchange Agreements, the holders agreed to exchange their convertible promissory notes of $330,000 and 33,000 warrants issued in connection with this debt for an aggregate of 82,500 shares of the Company’s common stock at a price of $4.00 per share. Consequently, the Company recorded a loss on debt extinguishment of $198,000 during the year ended December 31, 2020.                               
Loss on debt extinguishment (in Dollars)                                 198,000        
Series A Preferred Stock [Member]                                          
Stockholders’ Equity (Details) [Line Items]                                          
Preferred stock, shares authorized                                         1,000,000
Share outstanding                           0              
Redemption value (in Dollars)                                 $ 400,000        
Designated shares of preferred stock                                         1,000,000
Share issued                           0              
Series B Convertible Preferred Stock [Member]                                          
Stockholders’ Equity (Details) [Line Items]                                          
Preferred stock, shares authorized                           2,000   2,000 2,000     2,000  
Preferred stock, par value (in Dollars per share)                           $ 0.0001   $ 0.0001 $ 0.0001        
Preferred stock conversion, description           On April 15, 2020, the Company entered into Exchange Agreements with the holders of its Series B Preferred Stock whereby the holders agreed to exchange their 115 shares of Series B Preferred Stock with a stated value of $115,000 and 11,500 warrants issued in connection with the Series B Preferred Stock for an aggregate of 28,750 shares of the Company’s common stock at a price of $4.00 per share.                              
Share outstanding                                    
Designated shares of preferred stock                                       2,000  
Share issued                                    
Series C Preferred Stock [Member]                                          
Stockholders’ Equity (Details) [Line Items]                                          
Preferred stock, shares authorized   4,280                       4,280   4,280 4,280        
Preferred stock, par value (in Dollars per share)                           $ 0.0001   $ 0.0001 $ 0.0001        
Converted preferred stock             227                            
Convertible common stock             15,167                            
Share outstanding                           0   227        
Share issued                           0   227        
Series C Convertible Preferred Stock [Member]                                          
Stockholders’ Equity (Details) [Line Items]                                          
Preferred stock, shares authorized   4,280                           4,280          
Preferred stock, par value (in Dollars per share)                           $ 0.0001   $ 0.0001          
Convertible preferred stock stated value                               1,000          
Preferred stock outstanding, description                               A holder of Series C Convertible Preferred Stock may not convert any portion of the Series C Convertible Preferred Stock to the extent that the holder, together with its affiliates and any other person or entity acting as a group, would own more than 4.99% (or, upon election by a holder prior to issuance, 9.99%) of the outstanding shares of the Company’s common stock after conversion, which beneficial ownership limitation may be increased by the holder up to, but not exceeding, 9.99%.          
Share outstanding                               227          
Purchase agreement, description   On February 9, 2021, the Company entered into pursuant to securities purchase agreements with certain investors pursuant to which it sold warrants to purchase up to 285,067 shares of the Company’s common stock and 4,276 shares of the Company’s Series C Convertible Preferred Stock. The February Warrants are exercisable for a period of five years from the date of issuance at an exercise price of $15.00 per share, subject to adjustment. If, after a period of 180 days after the date of issuance of the February Warrants, a registration statement covering the resale of the February Warrant Shares is not effective, the holders may exercise the February Warrants by means of a cashless exercise. In addition, pursuant to the terms of the offering, the Company issued the Placement Agent Warrants to purchase up to an aggregate of 57,013 shares of common stock to its placement agents, or 10% of the shares of common stock issuable upon conversion of the Series C Preferred Stock and February Warrant Shares sold in the offering. The Placement Agent Warrants are exercisable for a period of five years from the closing date of the offering at an exercise price of $17.50 per share, subject to adjustment (see Series C Convertible Preferred Stock Financing above). Such warrants issued to various investors and to the placement agents were recorded as additional paid in capital with an offsetting debit applied against additional paid in capital, thus these warrants have no further accounting effect within the equity section.                                      
Designated shares of preferred stock   4,280                       4,280              
Preferred stock, stated value (in Dollars)                           $ 1,000              
Convertible preferred stock, description                           A holder of Series C Convertible preferred stock may not convert any portion of the Series C Convertible preferred stock to the extent that the holder, together with its affiliates and any other person or entity acting as a group, would own more than 4.99% (or, upon election by a holder prior to issuance, 9.99%) of the outstanding shares of the Company’s common stock after conversion, which beneficial ownership limitation may be increased by the holder up to, but not exceeding, 9.99%.              
Deemed dividend (in Dollars)   $ 1,403,997                                      
Series C Conversion Price [Member]                                          
Stockholders’ Equity (Details) [Line Items]                                          
Conversion price per share (in Dollars per share)                           $ 15   $ 15          
Series C Purchase Agreements [Member]                                          
Stockholders’ Equity (Details) [Line Items]                                          
Preferred stock conversion, description   On February 9, 2021 (the “Effectiveness Date”), the Company entered into securities purchase agreements (collectively, the “Series C Purchase Agreements”) with certain institutional and accredited investors for the sale of an aggregate of 4,276 shares of the Company’s Series C Convertible Preferred Stock and warrants (the “February Warrants”) to purchase up to 285,066 shares (the “February Warrant Shares”) of the Company’s common stock for gross proceeds of approximately $4,276,000, before deducting placement agent and other offering expenses of $481,898 which are offset against the proceeds in additional paid in capital. The offering closed on February 12, 2021. Accordingly, the Company recognized a total deemed dividend of $1,403,997 for the beneficial conversion feature in connection with the issuance of these Series C Convertible Preferred Stock.                                       
Subsequent financing, percentage                               50.00%          
Sale of aggregate shares   4,276                                      
Warrant to purchase shares   285,066                                      
Gross proceeds (in Dollars)   $ 4,276,000                                      
Offering expenses (in Dollars)   $ 481,898                                      
Board Granted [Member]                                          
Stockholders’ Equity (Details) [Line Items]                                          
Exercise price (in Dollars per share)                 $ 7.3                        
Risk free interest rate                 0.75%                        
Expected term                 2 years                        
Expected volatility                 0.00%                        
Aggregate of incentive stock options                 6,849                        
Stock option value (in Dollars)                 $ 30,224                        
Expected volatility                 115.00%                        
Fair value of unvested stock option                 30,224                        
Fair value of the unvested stock options (in Dollars)                           $ 15,122              
Issuance of deferred compensation balance (in Dollars)                           $ 15,122              
Omnibus Equity incentive Plan [Member]                                          
Stockholders’ Equity (Details) [Line Items]                                          
Shares of common stock reserved and avail for issuance                   170,000                      
Incentive Stock Option [Member]                                          
Stockholders’ Equity (Details) [Line Items]                                          
Risk free interest rate                           1.18%              
Expected dividend yield                           0.00%              
Expected term                           2 years              
Expected volatility                           117.00%              
Fair value of the unvested stock options (in Dollars)                           $ 59,322              
Stock option                           16,000              
Fair value of stock option (in Dollars)                           $ 94,915              
Stock-based Compensation (in Dollars)                           $ 23,540